A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.
There are 24 items
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of GRIFFIN (AFT-29) Among Clinically Relevant Subgroups
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 12-months of Maintenance Therapy (AFT-29)
An End-of-study Subgroup Analysis of Black Patients From the Phase 2 GRIFFIN (AFT-29) Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM)
Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple MyNewly diagnosed multiple myeloma, daratumumab, autologous stem cell transplanteloma (NDMM): Final Analysis of GRIFFIN